trial · primary record
azacytidine
Non-small Cell Lung Cancer (NSCLC)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2034-12-31 |
| Primary endpoint | Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of neoadjuvant aerosolized AZA in participants with operable early-stage NSCLC treated with standard of care (SOC) platinum-based chemotherapy and du... |
| Registry ID | NCT06694454 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:37.159Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06694454
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.